compounded semaglutide fda Compound versions of GLP-1 drugs for weight loss halted by FDA Warns Against Using Compounded

(3 April 2025)

Diabetes Drugs The same active ingredient can have very different FDA approvals, so the name on the box matters: Wegovy (semaglutide) FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition (and for adolescents 12 and older with a BMI at or above the 95th percentile for their age and sex)

Clinical Considerations and Prescription Process Consult with a healthcare provider experienced in prescribing semaglutide for weight loss

Hence, it is important for pharmaceutical manufacturers to understand the GLP-1 supply chain

Many patients also see better results when they combine semaglutide injections with consistent dietary changes and physical activity